Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Gene expression profiling informs HPV cervical histopathology but not recurrence/relapse after LEEP in ART-suppressed HIV+HPV+ women.

Papasavvas E, Kossenkov AV, Azzoni L, Zetola NM, Mackiewicz A, Ross BN, Fair M, Vadrevu S, Ramogola-Masire D, Sanne I, Firnhaber C, Montaner LJ.

Carcinogenesis. 2018 Oct 26. doi: 10.1093/carcin/bgy149. [Epub ahead of print]

PMID:
30364933
2.

BCL6 Inhibitor-Mediated Downregulation of Phosphorylated SAMHD1 and T Cell Activation Are Associated with Decreased HIV Infection and Reactivation.

Cai Y, Abdel-Mohsen M, Tomescu C, Xue F, Wu G, Howell BJ, Ai Y, Sun J, Azzoni L, Le Coz C, Romberg N, Montaner LJ.

J Virol. 2019 Jan 4;93(2). pii: e01073-18. doi: 10.1128/JVI.01073-18. Print 2019 Jan 15.

PMID:
30355686
3.

Analytical antiretroviral therapy interruption does not irreversibly change preinterruption levels of cellular HIV.

Papasavvas E, Lada SM, Joseph J, Yin X, Liu Q, Azzoni L, Mounzer K, Kostman JR, Richman D, Montaner LJ.

AIDS. 2018 Aug 24;32(13):1763-1772. doi: 10.1097/QAD.0000000000001909.

PMID:
30045057
4.

Analytical ART interruption does not irreversibly change pre-interruption levels of cellular HIV.

Papasavvas E, Lada SM, Joseph J, Yin X, Liu Q, Azzoni L, Mounzer K, Kostman JR, Richman D, Montaner LJ.

AIDS. 2018 Jun 11. doi: 10.1097/QAD.0000000000001909. [Epub ahead of print]

PMID:
29894387
5.

Immunologic Effects of Maraviroc in HIV-Infected Patients with Severe CD4 Lymphopenia Starting Antiretroviral Therapy: A Sub-Study of the CADIRIS Trial.

Belaunzarán-Zamudio PF, Azzoni L, Canaday DH, Caro-Vega YN, Clagett B, Rassool MS, Rodriguez B, Sanne I, Sereti I, Sierra-Madero JG, Lederman MM.

Pathog Immun. 2017;2(2):151-177. doi: 10.20411/pai.v2i2.181. Epub 2017 May 9.

6.

HCV viraemia associates with NK cell activation and dysfunction in antiretroviral therapy-treated HIV/HCV-co-infected subjects.

Papasavvas E, Azzoni L, Yin X, Liu Q, Joseph J, Mackiewicz A, Ross B, Lynn KM, Jacobson JM, Mounzer K, Kostman JR, Montaner LJ.

J Viral Hepat. 2017 Oct;24(10):865-876. doi: 10.1111/jvh.12714. Epub 2017 May 11.

7.

High-risk oncogenic HPV genotype infection associates with increased immune activation and T cell exhaustion in ART-suppressed HIV-1-infected women.

Papasavvas E, Surrey LF, Glencross DK, Azzoni L, Joseph J, Omar T, Feldman MD, Williamson AL, Siminya M, Swarts A, Yin X, Liu Q, Firnhaber C, Montaner LJ.

Oncoimmunology. 2016 Jan 19;5(5):e1128612. doi: 10.1080/2162402X.2015.1128612. eCollection 2016 May.

8.

Early ART Results in Greater Immune Reconstitution Benefits in HIV-Infected Infants: Working with Data Missingness in a Longitudinal Dataset.

Azzoni L, Barbour R, Papasavvas E, Glencross DK, Stevens WS, Cotton MF, Violari A, Montaner LJ.

PLoS One. 2015 Dec 15;10(12):e0145320. doi: 10.1371/journal.pone.0145320. eCollection 2015.

9.

Antiretroviral therapy in HIV-1-infected individuals with CD4 count below 100 cells/mm3 results in differential recovery of monocyte activation.

Patro SC, Azzoni L, Joseph J, Fair MG, Sierra-Madero JG, Rassool MS, Sanne I, Montaner LJ.

J Leukoc Biol. 2016 Jul;100(1):223-31. doi: 10.1189/jlb.5AB0915-406R. Epub 2015 Nov 25.

10.

HIV-1-negative female sex workers sustain high cervical IFNɛ, low immune activation, and low expression of HIV-1-required host genes.

Abdulhaqq SA, Zorrilla C, Kang G, Yin X, Tamayo V, Seaton KE, Joseph J, Garced S, Tomaras GD, Linn KA, Foulkes AS, Azzoni L, VerMilyea M, Coutifaris C, Kossenkov AV, Showe L, Kraiselburd EN, Li Q, Montaner LJ.

Mucosal Immunol. 2016 Jul;9(4):1027-38. doi: 10.1038/mi.2015.116. Epub 2015 Nov 11.

11.

Effect of the CCR5 antagonist maraviroc on the occurrence of immune reconstitution inflammatory syndrome in HIV (CADIRIS): a double-blind, randomised, placebo-controlled trial.

Sierra-Madero JG, Ellenberg SS, Rassool MS, Tierney A, Belaunzarán-Zamudio PF, López-Martínez A, Piñeirúa-Menéndez A, Montaner LJ, Azzoni L, Benítez CR, Sereti I, Andrade-Villanueva J, Mosqueda-Gómez JL, Rodriguez B, Sanne I, Lederman MM; CADIRIS study team.

Lancet HIV. 2014 Nov;1(2):e60-7. doi: 10.1016/S2352-3018(14)70027-X. Epub 2014 Oct 21. Erratum in: Lancet HIV. 2015 Oct;2(10):e416.

PMID:
26423989
12.

A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of a Chemokine Receptor 5 (CCR5) Antagonist to Decrease the Occurrence of Immune Reconstitution Inflammatory Syndrome in HIV-Infection: The CADIRIS Study.

Sierra-Madero JG, Ellenberg S, Rassool MS, Tierney A, Belaunzarán-Zamudio PF, López-Martínez A, Piñeirúa-Menéndez A, Montaner LJ, Azzoni L, Benítez CR, Sereti I, Andrade-Villanueva J, Mosqueda-Gómez JL, Rodriguez B, Sanne I, Lederman MM; CADIRIS study team.

Lancet HIV. 2014 Nov 1;1(2):e60-e67.

13.

Plasmacytoid dendritic cell and functional HIV Gag p55-specific T cells before treatment interruption can inform set-point plasma HIV viral load after treatment interruption in chronically suppressed HIV-1(+) patients.

Papasavvas E, Foulkes A, Yin X, Joseph J, Ross B, Azzoni L, Kostman JR, Mounzer K, Shull J, Montaner LJ.

Immunology. 2015 Jul;145(3):380-90. doi: 10.1111/imm.12452. Epub 2015 May 19.

14.

Identification of a 251 gene expression signature that can accurately detect M. tuberculosis in patients with and without HIV co-infection.

Dawany N, Showe LC, Kossenkov AV, Chang C, Ive P, Conradie F, Stevens W, Sanne I, Azzoni L, Montaner LJ.

PLoS One. 2014 Feb 25;9(2):e89925. doi: 10.1371/journal.pone.0089925. eCollection 2014.

15.

Association of HIV and ART with cardiometabolic traits in sub-Saharan Africa: a systematic review and meta-analysis.

Dillon DG, Gurdasani D, Riha J, Ekoru K, Asiki G, Mayanja BN, Levitt NS, Crowther NJ, Nyirenda M, Njelekela M, Ramaiya K, Nyan O, Adewole OO, Anastos K, Azzoni L, Boom WH, Compostella C, Dave JA, Dawood H, Erikstrup C, Fourie CM, Friis H, Kruger A, Idoko JA, Longenecker CT, Mbondi S, Mukaya JE, Mutimura E, Ndhlovu CE, Praygod G, Pefura Yone EW, Pujades-Rodriguez M, Range N, Sani MU, Schutte AE, Sliwa K, Tien PC, Vorster EH, Walsh C, Zinyama R, Mashili F, Sobngwi E, Adebamowo C, Kamali A, Seeley J, Young EH, Smeeth L, Motala AA, Kaleebu P, Sandhu MS; African Partnership for Chronic Disease Research (APCDR).

Int J Epidemiol. 2013 Dec;42(6):1754-71. doi: 10.1093/ije/dyt198. Review. Erratum in: Int J Epidemiol. 2016 Dec 1;45(6):2210-2211.

16.

Improved treatment for primary HIV infection by interferon-alfa therapy? Does HCV treatment in HIV/HCV coinfected patients help us to test this hypothesis? Reply to zur Wiesch and van Lunzen.

Azzoni L, Foulkes AS, Papasavvas E, Mexas AM, Lynn KM, Mounzer K, Tebas P, Jacobson JM, Frank I, O'Doherty U, Kostman J, Montaner LJ.

J Infect Dis. 2013 Jul 15;208(2):363. doi: 10.1093/infdis/jit160. Epub 2013 Apr 9. No abstract available.

PMID:
23570845
17.

Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration.

Azzoni L, Foulkes AS, Papasavvas E, Mexas AM, Lynn KM, Mounzer K, Tebas P, Jacobson JM, Frank I, Busch MP, Deeks SG, Carrington M, O'Doherty U, Kostman J, Montaner LJ.

J Infect Dis. 2013 Jan 15;207(2):213-22. doi: 10.1093/infdis/jis663. Epub 2012 Oct 26.

18.

Concurrent measures of total and integrated HIV DNA monitor reservoirs and ongoing replication in eradication trials.

Mexas AM, Graf EH, Pace MJ, Yu JJ, Papasavvas E, Azzoni L, Busch MP, Di Mascio M, Foulkes AS, Migueles SA, Montaner LJ, O'Doherty U.

AIDS. 2012 Nov 28;26(18):2295-306. doi: 10.1097/QAD.0b013e32835a5c2f.

19.

Prioritizing CD4 count monitoring in response to ART in resource-constrained settings: a retrospective application of prediction-based classification.

Azzoni L, Foulkes AS, Liu Y, Li X, Johnson M, Smith C, Kamarulzaman AB, Montaner J, Mounzer K, Saag M, Cahn P, Cesar C, Krolewiecki A, Sanne I, Montaner LJ.

PLoS Med. 2012;9(4):e1001207. doi: 10.1371/journal.pmed.1001207. Epub 2012 Apr 17.

20.

Antiretroviral therapy interruptions result in loss of protective humoral immunity to neoantigens in HIV-infected individuals.

Azzoni L, Foulkes AS, Firnhaber C, Yin X, Xiang ZQ, Li Y, Stevens W, Gross R, Ertl HC, Sanne I, Montaner LJ.

AIDS. 2012 Jul 17;26(11):1355-62. doi: 10.1097/QAD.0b013e328354648e.

21.

Natural killer cell activation distinguishes Mycobacterium tuberculosis-mediated immune reconstitution syndrome from chronic HIV and HIV/MTB coinfection.

Conradie F, Foulkes AS, Ive P, Yin X, Roussos K, Glencross DK, Lawrie D, Stevens W, Montaner LJ, Sanne I, Azzoni L.

J Acquir Immune Defic Syndr. 2011 Nov 1;58(3):309-18. doi: 10.1097/QAI.0b013e31822e0d15.

22.

Metabolic and anthropometric parameters contribute to ART-mediated CD4+ T cell recovery in HIV-1-infected individuals: an observational study.

Azzoni L, Foulkes AS, Firnhaber C, Yin X, Crowther NJ, Glencross D, Lawrie D, Stevens W, Papasavvas E, Sanne I, Montaner LJ.

J Int AIDS Soc. 2011 Jul 29;14:37. doi: 10.1186/1758-2652-14-37.

23.

Randomized trial of time-limited interruptions of protease inhibitor-based antiretroviral therapy (ART) vs. continuous therapy for HIV-1 infection.

Firnhaber C, Azzoni L, Foulkes AS, Gross R, Yin X, Van Amsterdam D, Schulze D, Glencross DK, Stevens W, Hunt G, Morris L, Fox L, Sanne I, Montaner LJ.

PLoS One. 2011;6(6):e21450. doi: 10.1371/journal.pone.0021450. Epub 2011 Jun 28.

24.

Increased microbial translocation in ≤ 180 days old perinatally human immunodeficiency virus-positive infants as compared with human immunodeficiency virus-exposed uninfected infants of similar age.

Papasavvas E, Azzoni L, Foulkes A, Violari A, Cotton MF, Pistilli M, Reynolds G, Yin X, Glencross DK, Stevens WS, McIntyre JA, Montaner LJ.

Pediatr Infect Dis J. 2011 Oct;30(10):877-82. doi: 10.1097/INF.0b013e31821d141e.

25.

Prediction based classification for longitudinal biomarkers.

Foulkes AS, Azzoni L, Li X, Johnson MA, Smith C, Mounzer K, Montaner LJ.

Ann Appl Stat. 2010 Sep;4(3):1476-1497.

26.

Association between HIV replication and serum leptin levels: an observational study of a cohort of HIV-1-infected South African women.

Azzoni L, Crowther NJ, Firnhaber C, Foulkes AS, Yin X, Glencross D, Gross R, Kaplan MD, Papasavvas E, Schulze D, Stevens W, van der Merwe T, Waisberg R, Sanne I, Montaner LJ.

J Int AIDS Soc. 2010 Sep 7;13:33. doi: 10.1186/1758-2652-13-33.

27.

Retention of functional DC-NK cross-talk following up to 18 weeks therapy interruptions in chronically suppressed HIV type 1+ subjects.

Papasavvas E, Chehimi J, Azzoni L, Pistilli M, Thiel B, Mackiewicz A, Creer S, Mounzer K, Kostman JR, Montaner LJ.

AIDS Res Hum Retroviruses. 2010 Oct;26(10):1047-9. doi: 10.1089/aid.2010.0020. Epub 2010 Aug 18. No abstract available.

28.

Tree-Based Methods for Discovery of Association between Flow Cytometry Data and Clinical Endpoints.

Eliot M, Azzoni L, Firnhaber C, Stevens W, Glencross DK, Sanne I, Montaner LJ, Foulkes AS.

Adv Bioinformatics. 2009;2009:235320. doi: 10.1155/2009/235320. Epub 2010 Jan 21.

29.

Delayed loss of control of plasma lipopolysaccharide levels after therapy interruption in chronically HIV-1-infected patients.

Papasavvas E, Pistilli M, Reynolds G, Bucki R, Azzoni L, Chehimi J, Janmey PA, DiNubile MJ, Ondercin J, Kostman JR, Mounzer KC, Montaner LJ.

AIDS. 2009 Jan 28;23(3):369-75. doi: 10.1097/QAD.0b013e32831e9c76.

30.

HIV type 1 viremia on ART is positively associated with polyclonal T cell proliferation in subjects with T cell IFN-gamma secretion levels comparable to those of uninfected subjects.

Papasavvas E, Moore EC, Sun J, Azzoni L, Pistilli M, Mounzer K, Shull J, Kostman JR, Montaner LJ.

AIDS Res Hum Retroviruses. 2008 Sep;24(9):1203-8. doi: 10.1089/aid.2008.0054.

31.
32.

Baseline viral load and immune activation determine the extent of reconstitution of innate immune effectors in HIV-1-infected subjects undergoing antiretroviral treatment.

Chehimi J, Azzoni L, Farabaugh M, Creer SA, Tomescu C, Hancock A, Mackiewicz A, D'Alessandro L, Ghanekar S, Foulkes AS, Mounzer K, Kostman J, Montaner LJ.

J Immunol. 2007 Aug 15;179(4):2642-50.

33.

Early and delayed benefits of HIV-1 suppression: timeline of recovery of innate immunity effector cells.

Azzoni L, Chehimi J, Zhou L, Foulkes AS, June R, Maino VC, Landay A, Rinaldo C, Jacobson LP, Montaner LJ.

AIDS. 2007 Jan 30;21(3):293-305.

PMID:
17255736
34.

Dendritic and natural killer cell subsets associated with stable or declining CD4+ cell counts in treated HIV-1-infected children.

Azzoni L, Rutstein RM, Chehimi J, Farabaugh MA, Nowmos A, Montaner LJ.

J Infect Dis. 2005 May 1;191(9):1451-9. Epub 2005 Mar 30.

PMID:
15809903
35.

Randomized, controlled trial of therapy interruption in chronic HIV-1 infection.

Papasavvas E, Kostman JR, Mounzer K, Grant RM, Gross R, Gallo C, Azzoni L, Foulkes A, Thiel B, Pistilli M, Mackiewicz A, Shull J, Montaner LJ.

PLoS Med. 2004 Dec;1(3):e64. Epub 2004 Dec 28.

36.

Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15.

Wysocka M, Benoit BM, Newton S, Azzoni L, Montaner LJ, Rook AH.

Blood. 2004 Dec 15;104(13):4142-9. Epub 2004 Aug 24.

37.

Lessons learned from HIV treatment interruption: safety, correlates of immune control, and drug sparing.

Azzoni L, Papasavvas E, Montaner LJ.

Curr HIV Res. 2003 Jul;1(3):329-42. Review.

PMID:
15046257
38.

HIV-1 transmission and cytokine-induced expression of DC-SIGN in human monocyte-derived macrophages.

Chehimi J, Luo Q, Azzoni L, Shawver L, Ngoubilly N, June R, Jerandi G, Farabaugh M, Montaner LJ.

J Leukoc Biol. 2003 Nov;74(5):757-63. Epub 2003 Aug 21.

PMID:
12960240
39.

Sustained impairment of IFN-gamma secretion in suppressed HIV-infected patients despite mature NK cell recovery: evidence for a defective reconstitution of innate immunity.

Azzoni L, Papasavvas E, Chehimi J, Kostman JR, Mounzer K, Ondercin J, Perussia B, Montaner LJ.

J Immunol. 2002 Jun 1;168(11):5764-70.

40.

Persistent decreases in blood plasmacytoid dendritic cell number and function despite effective highly active antiretroviral therapy and increased blood myeloid dendritic cells in HIV-infected individuals.

Chehimi J, Campbell DE, Azzoni L, Bacheller D, Papasavvas E, Jerandi G, Mounzer K, Kostman J, Trinchieri G, Montaner LJ.

J Immunol. 2002 May 1;168(9):4796-801.

42.

A serine 37 mutation associated with two missense mutations at highly conserved regions of p53 affect pro-apoptotic genes expression in a T-lymphoblastoid drug resistant cell line.

Cinti C, Claudio PP, Luca AD, Cuccurese M, Howard CM, D'Esposito M, Paggi MG, Sala DL, Azzoni L, Halazonetis TD, Giordano A, Maraldi NM.

Oncogene. 2000 Oct 19;19(44):5098-105.

43.

Differential role of p38 and c-Jun N-terminal kinase 1 mitogen-activated protein kinases in NK cell cytotoxicity.

Trotta R, Fettucciari K, Azzoni L, Abebe B, Puorro KA, Eisenlohr LC, Perussia B.

J Immunol. 2000 Aug 15;165(4):1782-9.

44.

Dependence of both spontaneous and antibody-dependent, granule exocytosis-mediated NK cell cytotoxicity on extracellular signal-regulated kinases.

Trotta R, Puorro KA, Paroli M, Azzoni L, Abebe B, Eisenlohr LC, Perussia B.

J Immunol. 1998 Dec 15;161(12):6648-56.

45.

Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells.

Zamai L, Ahmad M, Bennett IM, Azzoni L, Alnemri ES, Perussia B.

J Exp Med. 1998 Dec 21;188(12):2375-80.

46.

Differential transcriptional regulation of CD161 and a novel gene, 197/15a, by IL-2, IL-15, and IL-12 in NK and T cells.

Azzoni L, Zatsepina O, Abebe B, Bennett IM, Kanakaraj P, Perussia B.

J Immunol. 1998 Oct 1;161(7):3493-500.

47.

Definition of a natural killer NKR-P1A+/CD56-/CD16- functionally immature human NK cell subset that differentiates in vitro in the presence of interleukin 12.

Bennett IM, Zatsepina O, Zamai L, Azzoni L, Mikheeva T, Perussia B.

J Exp Med. 1996 Nov 1;184(5):1845-56. Erratum in: J Exp Med 1997 Mar 17;185(6):1150-1.

48.

IL-12-induced activation of NK and T cells occurs in the absence of immediate-early activation gene expression.

Azzoni L, Kanakaraj P, Zatsepina O, Perussia B.

J Immunol. 1996 Oct 15;157(8):3235-41.

PMID:
8871617
50.

Ligand binding to Fc gamma R induces c-myc-dependent apoptosis in IL-2-stimulated NK cells.

Azzoni L, Anegon I, Calabretta B, Perussia B.

J Immunol. 1995 Jan 15;154(2):491-9.

PMID:
7814862

Supplemental Content

Loading ...
Support Center